Exelixis, Inc. - Common Stock (EXEL)
Frequently Asked Questions About Exelixis, Inc. - Common Stock (EXEL)
Does Exelixis conduct international clinical trials?
Yes, Exelixis conducts international clinical trials to evaluate its therapies in diverse populations and settings. By engaging in global research efforts, Exelixis can gather robust clinical data that informs treatment options across different regions and improves patient care worldwide.
How does Exelixis contribute to cancer research?
Exelixis contributes to cancer research through its commitment to innovative drug discovery and development, clinical trials, and collaborations with academic institutions and industry partners. By focusing on targeted therapies and providing financial support for research initiatives, Exelixis plays a significant role in advancing the understanding of cancer biology and finding effective treatments.
How does Exelixis engage with the community?
Exelixis engages with the community through various initiatives aimed at raising awareness about cancer, supporting research efforts, and participating in health advocacy programs. The company is committed to corporate social responsibility, collaborating with non-profit organizations and cancer advocacy groups to improve patient outcomes and promote access to care.
How does Exelixis ensure product quality?
Exelixis ensures product quality through rigorous quality control processes that adhere to Good Manufacturing Practices (GMP) and other regulatory standards. This commitment to quality extends through all phases of research, development, and production, ensuring that their therapies are safe and effective for patients.
How does Exelixis support patients and healthcare providers?
Exelixis supports patients and healthcare providers by offering comprehensive resources and patient assistance programs designed to provide access to their therapies. The company also engages in educational initiatives to raise awareness about cancer treatments and supports healthcare providers with information regarding the use of Exelixis' products in clinical practice.
Is Exelixis a publicly traded company?
Yes, Exelixis, Inc. is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol 'EXEL'. As a publicly traded entity, it engages in financial reporting and disclosures required by regulatory authorities, enabling investors to actively trade its stock.
What are some key products developed by Exelixis?
Exelixis is known for its leading cancer therapy, cabozantinib (brand name Cabometyx), which is approved for the treatment of various types of kidney cancer and hepatocellular carcinoma. Additionally, Exelixis has developed other products and therapies that focus on different cancer types, aiming to provide comprehensive therapeutic options to patients.
What are the future goals of Exelixis?
The future goals of Exelixis include expanding its portfolio of approved therapies, advancing additional candidates through clinical development, and increasing its global presence in the oncology market. The company aims to meet the diverse needs of cancer patients and clinicians, ultimately improving survival rates and quality of life for individuals affected by cancer.
What does Exelixis, Inc. do?
Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of cancer. The company's mission is to help patients with cancer regain their lives by providing them with groundbreaking treatment options based on its proprietary drug discovery platform. Exelixis specializes in advanced cancer therapies that target specific pathways involved in tumor growth and progression.
What is cabozantinib?
Cabozantinib is a small molecule drug developed by Exelixis that targets multiple receptor tyrosine kinases involved in cancer progression and metastasis. It is designed to inhibit tumor growth by blocking pathways that contribute to cancer cell survival and angiogenesis, making it effective in the treatment of various cancers, including renal cell carcinoma.
What is Exelixis' approach to drug development?
Exelixis takes a targeted approach to drug development, focusing on the identification of specific pathways that drive cancer progression. By utilizing its proprietary discovery platform, Exelixis aims to create therapies that not only inhibit tumor growth but also enhance the immune response against tumors, offering a comprehensive strategy for cancer management.
What is the focus of Exelixis' clinical trials?
The focus of Exelixis' clinical trials is to evaluate the safety and efficacy of its cancer therapies, particularly cabozantinib and its potential new treatments in various cancer indications. The company conducts both company-sponsored and collaborative trials to assess new combinations and treatment regimens in a range of oncology settings.
What is the significance of Exelixis' stock performance?
The stock performance of Exelixis, Inc. reflects investor confidence in the company's growth potential and its ability to deliver effective cancer therapies. Fluctuations in the stock price may indicate market reactions to clinical trial results, regulatory approvals, and overall company performance, which are key indicators for potential investors and stakeholders.
What partnerships does Exelixis have?
Exelixis has established partnerships with several leading pharmaceutical companies and research institutions to enhance its drug development capabilities. These partnerships aim to leverage shared resources, expertise, and innovative technologies in the field of oncology to accelerate the development of new therapies and improve treatment outcomes for patients.
What regulatory approvals has Exelixis received?
Exelixis has received multiple regulatory approvals from the U.S. Food and Drug Administration (FDA) for its lead product cabozantinib and other investigational drugs. These approvals are based on extensive clinical trial data demonstrating the safety and efficacy of their therapies in treating specific cancer types, allowing them to be prescribed by healthcare professionals.
When was Exelixis, Inc. founded?
Exelixis, Inc. was founded in 1995. The company was established to develop targeted therapies for cancer, leveraging its unique platform for drug discovery and development to create innovative treatments that address unmet medical needs in oncology.
Where is Exelixis, Inc. headquartered?
Exelixis, Inc. is headquartered in South San Francisco, California. This strategic location places the company right in the heart of one of the world’s leading biotechnology hubs, allowing easy access to top talent, research institutions, and a collaborative network that is crucial for innovation in drug development.
Who are the key executives at Exelixis, Inc.?
Exelixis, Inc. is led by a team of experienced executives, including Dr. Michael M. Morrissey, the President and CEO. The leadership team brings a wealth of experience from both the pharmaceutical and biotechnology industries, and their expertise is critical to Exelixis' mission of developing innovative cancer therapies.
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 37.04
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 11.67B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 315.05M shares outstanding.